Changeflow GovPing Pharma & Drug Safety Patent Application for Reducing Blood Glucose w...
Routine Notice Added Draft

Patent Application for Reducing Blood Glucose with Plants

Favicon for changeflow.com ChangeBridge: Patent Apps - Therapeutics (A61P)
Published September 26th, 2024
Detected March 26th, 2026
Email

Summary

The USPTO has published a new patent application (US20260083803A1) detailing methods and compositions for reducing fasting blood glucose in mammals using plants like Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

What changed

This document is a publication of a patent application filed with the USPTO, specifically application number 18898639, titled "METHODS AND COMPOSITIONS FOR REDUCING FASTING BLOOD GLUCOSE IN A MAMMAL USING NATURALLY OCCURING PLANTS AND SPICES." The application, filed on September 26, 2024, describes the use of Dichrostachys glomerata or Cissus quadrangularis to potentially increase GLP-1 levels and reduce blood glucose, visceral fat, cholesterol, and food intake. The inventors listed are Shil Kothari and Julius Enyoug Oben.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in therapeutic approaches for managing blood glucose levels. Companies involved in pharmaceutical development, nutraceuticals, or health supplements may find the disclosed methods and compositions of interest for research and development purposes. The application is scheduled for publication on March 26, 2026.

Source document (simplified)

← USPTO Patent Applications

METHODS AND COMPOSITIONS FOR REDUCING FASTING BLOOD GLUCOSE IN A MAMMAL USING NATURALLY OCCURING PLANTS AND SPICES

Application US20260083803A1 Kind: A1 Mar 26, 2026

Inventors

Shil Kothari, Julius Enyoug Oben

Abstract

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing fasting blood glucose in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

CPC Classifications

A61K 36/48 A61P 3/10 A61K 2236/17 A61K 2236/33

Filing Date

2024-09-26

Application No.

18898639

View original document →

Classification

Agency
USPTO
Published
September 26th, 2024
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260083803A1

Who this affects

Applies to
Drug manufacturers Healthcare providers Patients
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Therapeutic Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Food Safety Healthcare

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.